AbbVie (NYSE:ABBV) Announces Quarterly Earnings Results

AbbVie (NYSE:ABBV) posted its quarterly earnings results on Friday. The company reported $3.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.73 by $0.09, FiscalAI reports. The business had revenue of $17.40 billion during the quarter, compared to analyst estimates of $17.32 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company’s revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the business posted $1.86 earnings per share.

Here are the key takeaways from AbbVie’s conference call:

• AbbVie raised its full-year outlook after third-quarter adjusted EPS of $3.82 and revenue of $17.4 billion exceeded expectations. Full-year revenue guidance increased by $200 million to approximately $67.8 billion, while adjusted EPS guidance rose to $13.95–$13.99.
• Immunology remained the primary growth engine, with SKYRIZI sales up 22.9% operationally to nearly $5.8 billion and RINVOQ sales up 24.3% to $2.7 billion. AbbVie expects further momentum from SKYRIZI’s newly approved subcutaneous Crohn’s induction regimen and potential RINVOQ approvals in vitiligo and alopecia areata.
• AbbVie highlighted several pipeline and portfolio catalysts, including FDA approval of JUVMO for Parkinson’s disease, positive phase III data for etentamig in multiple myeloma, and a 51% reduction in disease progression or death with EPKINLY plus R-CHOP in frontline DLBCL. Regulatory submissions and potential approvals are expected across these programs in 2027.
• Legacy and pressured businesses continued to weigh on results: HUMIRA sales fell 30.6% due to biosimilar competition, IMBRUVICA declined 26.1% amid IRA pricing and share pressure, and aesthetics revenue fell 1.8% as JUVÉDERM remained weak. AbbVie also expects a gradual JUVMO launch because broader Medicare coverage is not expected until 2028.
• Strong cash generation supported a 5.2% quarterly dividend increase to $1.82 per share and continued business-development capacity. Management said future deals are likely to be bolt-on acquisitions focused on differentiated assets in immunology, neuroscience, oncology, and obesity rather than another transformational transaction.

AbbVie Trading Up 1.3%

AbbVie stock traded up $3.76 during midday trading on Friday, hitting $294.55. 3,476,379 shares of the stock were exchanged, compared to its average volume of 6,312,749. The stock’s 50-day simple moving average is $268.69 and its 200 day simple moving average is $236.86. The stock has a market capitalization of $520.40 billion, a price-to-earnings ratio of 83.17, a PEG ratio of 1.31 and a beta of 0.24. AbbVie has a fifty-two week low of $190.75 and a fifty-two week high of $298.74.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.3%. AbbVie’s dividend payout ratio is currently 195.48%.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie reported adjusted earnings of $3.82 per share, above the roughly $3.73–$3.74 consensus, while revenue rose 10.3% year over year to $17.404 billion, also topping estimates. AbbVie Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: The immunology portfolio was the primary growth engine: Skyrizi revenue reached $5.776 billion and Rinvoq generated $2.706 billion, helping total immunology revenue grow 16.3%. Neuroscience revenue also rose 19.4%, led by Vraylar, Botox Therapeutic, and migraine treatments. ABBV Beats on Q3 Earnings and Sales
• Positive Sentiment: Management raised 2026 adjusted EPS guidance from $13.76–$13.96 to $13.95–$13.99. AbbVie also announced a 5.2% increase to its 2027 dividend, supporting the stock’s income-investment appeal.
• Positive Sentiment: QULIPTA outperformed topiramate in a Phase 3 migraine-prevention study, potentially strengthening AbbVie’s neuroscience pipeline and future growth prospects. QULIPTA Phase 3 Migraine Study
• Neutral Sentiment: AbbVie completed its acquisition of Apogee Therapeutics, deepening its immunology pipeline. The deal may improve long-term growth, but integration and development costs remain considerations.
• Negative Sentiment: Humira revenue fell 31.2% to $683 million as biosimilar competition continued. Aesthetics revenue also declined 1.4%, while the stock’s elevated valuation leaves less room for execution misses.

Analysts Set New Price Targets

Several analysts have weighed in on ABBV shares. Wall Street Zen cut AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 5th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $280.00 price target on shares of AbbVie in a research report on Tuesday, October 13th. UBS Group increased their price target on AbbVie from $260.00 to $275.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 6th. Erste Group Bank raised AbbVie from a “hold” rating to a “buy” rating in a research note on Wednesday, August 5th. Finally, Barclays increased their target price on shares of AbbVie from $300.00 to $325.00 and gave the stock an “overweight” rating in a report on Wednesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $279.86.

Insider Buying and Selling at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is currently owned by corporate insiders.

About AbbVie

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.